Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jan;40(1):25-32.
doi: 10.1007/s10067-020-05207-z. Epub 2020 Jun 6.

Molecular mechanisms and clinical studies of iguratimod for the treatment of ankylosing spondylitis

Suling Liu  1   2 , Yang Cui  3 , Xiao Zhang  2
Affiliations
Review

Molecular mechanisms and clinical studies of iguratimod for the treatment of ankylosing spondylitis

Suling Liu et al. Clin Rheumatol. 2021 Jan.

Abstract

Iguratimod (IGU) is a novel small molecule anti-rheumatic drug with the effect of non-steroidal anti-inflammatory drug and disease-modifying anti-rheumatic drug. IGU has various mechanisms of action, including inhibition of prostaglandin E2, tumor necrosis factor-α (TNF-α), interleukin-17 (IL-17) production, inhibition of macrophage migration inhibitory factor (MIF)-induced proinflammatory effects, inhibition of osteoclastogenesis, and promotion of osteoblastic differentiation. Ankylosing spondylitis (AS) is the major subtype of spondyloarthritis that affects the axial skeleton, causing inflammatory back pain, which can lead to impairments in structure and function and a decrease in quality of life. Theories on pathogenesis of AS include misfolding of human leukocyte antigen-B27 during its assembly leading to endoplasmic reticulum stress and unfolded protein response (UPR). Activation of UPR genes results in release of TNF-α and IL-17, which have been shown to be important in the development of AS. In addition, current evidence suggests the importance of cyclooxygenase-2/prostaglandin E2 pathway and MIF in the pathogenesis of AS. Current drugs for the treatment of AS are limited and exploration of effective drugs is needed. IGU may be effective for the treatment of AS given that its mechanisms of action are closely related to the pathogenesis of AS. In fact, several small-scale clinical trials have shown the efficacy of IGU for the treatment of AS. This article reviews the molecular mechanisms of IGU that are related to the pathogenesis of AS and clinical trials of IGU for the treatment of AS, providing a reference for future clinical application of IGU for AS.

Keywords: Ankylosing spondylitis; Cyclooxygenase-2/prostaglandin E2; Iguratimod; Interleukin-17; Macrophage migration inhibitory factor; Tumor necrosis factor-α.

PubMed Disclaimer

References

    1. Jiang H, Gao H, Wang Q, Wang M, Wu B (2020) Molecular mechanisms and clinical application of Iguratimod: a review. Biomed Pharmacother 122:109704 - PubMed
    1. Tanaka K, Kawasaki H, Kurata K et al (1995) T-614, a novel antirheumatic drug, inhibits both the activity and induction of cyclooxygenase-2 (COX-2) in cultured fibroblasts. Jpn J Pharmacol 67(4):305–314 - PubMed
    1. Aikawa Y, Yamamoto M, Yamamoto T et al (2002) An anti-rheumatic agent T-614 inhibits NF-kappaB activation in LPS- and TNF-alpha-stimulated THP-1 cells without interfering with IkappaBalpha degradation. Inflamm Res 51(4):188–194 - PubMed
    1. Kohno M, Aikawa Y, Tsubouchi Y et al (2001) Inhibitory effect of T-614 on tumor necrosis factor-alpha induced cytokine production and nuclear factor-kappaB activation in cultured human synovial cells. J Rheumatol 28(12):2591–2596 - PubMed
    1. Li G, Yamasaki R, Fang M et al (2018) Novel disease-modifying anti-rheumatic drug iguratimod suppresses chronic experimental autoimmune encephalomyelitis by down-regulating activation of macrophages/microglia through an NF-κB pathway. Sci Rep 8(1):1933 - PubMed - PMC

LinkOut - more resources